Remove Customer Development Remove Finance Remove IPO Remove Marketing
article thumbnail

Can You Trust Any vc's Under 40?

Steve Blank

To do this they have to accomplish five things; 1) get deal flow – via networking and legwork, they identify likely industries, companies and teams with the potential for rapid growth (less than 10 years), 2) evaluate those companies and teams on the basis of technology, market opportunity, and team.

article thumbnail

Innovation, Change and the Rest of Your Life

Steve Blank

I’ve seen the Valley grow from Sunnyvale to Santa Clara to today where it stretches from San Jose to South of Market in San Francisco. For life sciences it was the Genentech IPO in 1980 that proved to investors that life science startups could make them a ton of money. And while new markets were created (i.e.

Restful 227
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Reinventing Life Science Startups – Medical Devices and Digital Health

Steve Blank

Class III devices are generally the highest risk devices and must be approved by the FDA before they are marketed. Class III medical devices that are high risk or novel devices for which no “predicate device” exist require clinical trials of the medical device a PMA (Pre-Market Approval). Venture Capital Issues. Regulatory Issues.

Startup 296
article thumbnail

Welcome to the Lost Decade (for Entrepreneurs, IPO’s and VC’s)

Steve Blank

The collapse of the IPO market and dysfunctional math in the venture capital community has stacked the odds against you. Startup lifecycle in an IPO Market. Netscape’s 1995 IPO changed the rules. Suddenly there was a public market for companies with limited revenue and no profit. Here’s why.

article thumbnail

The rise of the “successful” unsustainable company

A Smart Bear: Startups and Marketing for Geeks

.” Here’s the summary of his track record (excerpted from the Fast Company article): Forefront — IPO’ed in 1995 by CBT — CBT stock fell 85% in 1998 and prompted class-action lawsuits. invested, IPO’ed in 2000 for $32/share — stock price now $2. from an IPO under a year ago of $10.

IPO 240
article thumbnail

Vertical Markets 4: Putting it All Together « Steve Blank

Steve Blank

In the last three posts, we drew the relationship of market risk and invention risk with vertical markets and pointed out verticals where customer development would be useful. In contrast to simply executing your business plan, the Customer Development process is built on low-cost and continuous learning and iterating.

Vertical 123
article thumbnail

How Scientists and Engineers Got It Right, and VC’s Got It Wrong

Steve Blank

It wasn’t pure research, but rather a culture of taking sufficient risks to get to market. In 1960’s and ‘70’s few MBA’s would give up a lucrative career in management, finance or Wall Street to join a bunch of technical lunatics. So the engineers taught themselves how to become marketers, sales people and CEO’s.

Engineer 307